In this episode, the editorial team discussed Pfizer’s new oral antiviral pill for the treatment of COVID-19. Pfizer released data from an interim analysis of a Phase III trial evaluating the drug, which shows that it can reduce the risk of hospitalizations by almost 90 percent. It also prevented COVID-19 related deaths in the study. The results were so strong that an independent data monitoring committee and the FDA told Pfizer they could stop enrolling participants in the trial. Ayesha and the team discussed the convenience of an oral medication for COVID-19, and how such drugs appear to be more accepted than preventative vaccines among some circles of people.The podcast also features a discussion on the recent FDA approval of AbbVie’s eyedrop for the treatment of presbyopia, or age-related deficits in near vision. The condition is currently treated with prescription “reading glasses” or contact lenses. With almost half of all adult Americans having the condition, there is a significant market for new treatments in the area. The editorial team discussed the advantages of an eyedrop over glasses, and how personal preferences may dictate what patients choose. Read the full articles here: Pfizer’s COVID-19 Antiviral Pill Cuts Hospitalizations by 90 Percent and May Eliminate All DeathsFDA Approves AbbVie’s Vuity as the First Eyedrop for PresbyopiaFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured